Chitosan for mucosal vaccination.

The striking advantage of mucosal vaccination is the production of local antibodies at the sites where pathogens enter the body. Because vaccines alone are not sufficiently taken up after mucosal administration, they need to be co-administered with penetration enhancers, adjuvants or encapsulated in particles. Chitosan easily forms microparticles and nanoparticles which encapsulate large amounts of antigens such as ovalbumin, diphtheria toxoid or tetanus toxoid. It has been shown that ovalbumin loaded chitosan microparticles are taken up by the Peyer's patches of the gut associated lymphoid tissue (GALT). This unique uptake demonstrates that chitosan particulate drug carrier systems are promising candidates for oral vaccination. Additionally, after co-administering chitosan with antigens in nasal vaccination studies, a strong enhancement of both mucosal and systemic immune responses is observed. This makes chitosan very suitable for nasal vaccine delivery. In conclusion, chitosan particles, powders and solutions are promising candidates for mucosal vaccine delivery. Mucosal vaccination not only reduces costs and increases patient compliance, but also complicates the invasion of pathogens through mucosal sites.

[1]  M. Kieny,et al.  Mucosal immunity and tolerance: relevance to vaccine development , 1999, Immunological reviews.

[2]  M. Brook,et al.  Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge. , 1998, Vaccine.

[3]  M. Jang,et al.  Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles. , 1999, Vaccine.

[4]  D. Cremaschi,et al.  Selective transport of microparticles across Peyer's patch follicle‐associated M cells from mice and rats , 1995, Experimental physiology.

[5]  D. Rahman,et al.  Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. , 1997, Vaccine.

[6]  P. Couvreur,et al.  Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres. , 1998, Vaccine.

[7]  M. Alonso,et al.  Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .

[8]  M. Alonso,et al.  Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron-emulsions , 1997 .

[9]  J. Biewenga,et al.  The role of nasopharyngeal lymphoid tissue. , 1992, Immunology today.

[10]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.

[11]  L. Illum,et al.  Chitosan and its use as a pharmaceutical excipient. , 1998, Pharmaceutical research.

[12]  J L Pedraz,et al.  Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[13]  R. Rappuoli,et al.  Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. , 1998, Vaccine.

[14]  J. Eyles,et al.  Oral and nasal immunization with microencapsulated clinically relevant proteins , 1998 .

[15]  A. Jones,et al.  Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. , 1974, Gastroenterology.

[16]  H E Junginger,et al.  In Vivo Uptake of Chitosan Microparticles by Murine Peyer's Patches: Visualization Studies using Confocal Laser Scanning Microscopy and Immunohistochemistry , 2001, Journal of drug targeting.

[17]  Y. Murata,et al.  Preparation of alginate gel beads containing chitosan salt and their function , 1999 .

[18]  P. G. Seferian,et al.  Immune stimulating activity of two new chitosan containing adjuvant formulations. , 2000, Vaccine.

[19]  H E Junginger,et al.  Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. , 2001, Biomaterials.

[20]  D. McCarthy,et al.  Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose , 1992 .

[21]  R. Rappuoli,et al.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. , 2000, Vaccine.

[22]  M. Roberts,et al.  Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens , 2000, Infection and Immunity.

[23]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .

[24]  J. Mcghee,et al.  The mucosal immune system: from fundamental concepts to vaccine development. , 1992, Vaccine.

[25]  J. Mcghee,et al.  Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. , 1987, Advances in immunology.

[26]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.